STOCK TITAN

Zomedica Announces Sponsorship of Educational Presentations at the Fetch Coastal Conference

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Zomedica Corp. (NYSE American:ZOM) has announced its sponsorship of educational programs at the upcoming Fetch Coastal conference in Atlantic City, NJ from October 14-16, 2024. The company will showcase its innovative veterinary products, including the TRUFORMA® diagnostic platform, TRUVIEW™ digital microscope, PulseVet® shock wave platform, and VETGuardian® remote monitor.

Zomedica is sponsoring presentations by leading veterinary experts, including:

  • Dr. Shadi J. Ireifej on Brachycephalic Airway Syndrome
  • Dr. Adam Christman on pain management modalities
  • Steve Dale on separation distress in pets
The company will be exhibiting at Booth #217 during the conference, which is described as a cornerstone event in the veterinary industry for the east coast.

Zomedica Corp. (NYSE American:ZOM) ha annunciato il suo patrocinio a programmi educativi durante la prossima Fetch Coastal conference ad Atlantic City, NJ, dal 14 al 16 ottobre 2024. L'azienda presenterà i suoi prodotti veterinari innovativi, tra cui la piattaforma diagnostica TRUFORMA®, il microscopio digitale TRUVIEW™, la piattaforma ad onde d'urto PulseVet® e il monitor remoto VETGuardian®.

Zomedica sponsorizzerà presentazioni di esperti veterinari di spicco, tra cui:

  • Dr. Shadi J. Ireifej sul Sindrome delle Vie Aeree Brachicefaliche
  • Dr. Adam Christman sulle modalità di gestione del dolore
  • Steve Dale sul disagio da separazione negli animali domestici
La società esporrà allo Stand #217 durante la conferenza, descritta come un evento fondamentale per l'industria veterinaria sulla costa est.

Zomedica Corp. (NYSE American:ZOM) ha anunciado su patrocinio a programas educativos en la próxima Fetch Coastal conference en Atlantic City, NJ, del 14 al 16 de octubre de 2024. La compañía mostrará sus innovadores productos veterinarios, incluyendo la plataforma de diagnóstico TRUFORMA®, el microscopio digital TRUVIEW™, la plataforma de ondas de choque PulseVet® y el monitor remoto VETGuardian®.

Zomedica patrocinará presentaciones de expertos veterinarios reconocidos, entre ellos:

  • Dr. Shadi J. Ireifej sobre el Síndrome de Vías Respiratorias Brachicefálicas
  • Dr. Adam Christman sobre modalidades de manejo del dolor
  • Steve Dale sobre el malestar por separación en mascotas
La empresa estará exhibiendo en el Stand #217 durante la conferencia, que se describe como un evento clave en la industria veterinaria de la costa este.

조메디카 주식회사 (NYSE American: ZOM)가 2024년 10월 14일부터 16일까지 뉴저지 애틀랜틱시티에서 열리는 Fetch Coastal conference의 교육 프로그램을 후원한다고 발표했습니다. 이 회사는 TRUFORMA® 진단 플랫폼, TRUVIEW™ 디지털 현미경, PulseVet® 충격파 플랫폼, VETGuardian® 원격 모니터를 포함한 혁신적인 수의학 제품을 전시할 예정입니다.

조메디카는 다음의 주요 수의학 전문가들의 발표를 후원할 예정입니다:

  • Dr. Shadi J. Ireifej 의 브라키셰팔기도의 증후군
  • Dr. Adam Christman 의 통증 관리 방법
  • Steve Dale 의 반려동물 이별 불안
회사는 이 회의 동안 부스 #217에서 전시할 예정이며, 이는 동부 해안에서 수의학 산업의 핵심 행사로 묘사됩니다.

Zomedica Corp. (NYSE American:ZOM) a annoncé son parrainage de programmes éducatifs lors de la prochaine Fetch Coastal conference à Atlantic City, NJ, du 14 au 16 octobre 2024. L'entreprise présentera ses produits vétérinaires innovants, y compris la plateforme de diagnostic TRUFORMA®, le microscope numérique TRUVIEW™, la plateforme d'onde de choc PulseVet® et le moniteur à distance VETGuardian®.

Zomedica parrainera des présentations d'experts vétérinaires reconnus, notamment :

  • Dr. Shadi J. Ireifej sur le Syndrome des Voies Respiratoires Brachycéphales
  • Dr. Adam Christman sur les modalités de gestion de la douleur
  • Steve Dale sur l'anxiété de séparation chez les animaux de compagnie
L'entreprise exposera au stand #217 pendant la conférence, qui est décrite comme un événement clé dans l'industrie vétérinaire sur la côte est.

Zomedica Corp. (NYSE American:ZOM) hat seine Unterstützung für Bildungsprogramme auf der kommenden Fetch Coastal conference in Atlantic City, NJ, vom 14. bis 16. Oktober 2024, bekannt gegeben. Das Unternehmen wird seine innovativen veterinärmedizinischen Produkte präsentieren, darunter die diagnostische Plattform TRUFORMA®, das digitale Mikroskop TRUVIEW™, die Stoßwellenplattform PulseVet® und den Fernmonitor VETGuardian®.

Zomedica wird Vorträge von führenden Veterinärmedizinern sponsern, darunter:

  • Dr. Shadi J. Ireifej über das Brachycephalic Airway Syndrome
  • Dr. Adam Christman über Schmerzmanagement-Methoden
  • Steve Dale über Trennungsangst bei Haustieren
Das Unternehmen wird während der Konferenz am Stand #217 ausstellen, der als Schlüsselveranstaltung in der Veterinärbranche an der Ostküste beschrieben wird.

Positive
  • Sponsorship of educational programs at a major veterinary conference increases brand visibility
  • Opportunity to showcase innovative veterinary products to thousands of animal health professionals
  • Presentations by leading experts featuring Zomedica's product applications
Negative
  • None.

Leading veterinary experts to present educational programs featuring Zomedica product applications at the Fetch dvm360 Veterinary Conference

ANN ARBOR, MI / ACCESSWIRE / October 15, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced its sponsorship of educational programs at the upcoming Fetch Coastal, formerly the Atlantic Coast Veterinary Conference, in Atlantic City, NJ from October 14-16 , 2024.

"The Fetch Coastal conference is a cornerstone event in the veterinary industry for the east coast, bringing together the brightest minds and latest innovations," remarked Nicole Westfall, Zomedica's Senior Vice President of Marketing. "This gathering provides an unparalleled platform for Zomedica to showcase our cutting-edge products to thousands of dedicated animal health professionals. The conference's dynamic environment perfectly aligns with our mission to revolutionize veterinary care through technology."

Kevin Klass, Zomedica's Senior Vice President of Sales, elaborated, "At Fetch Coastal, we have the unique opportunity to demonstrate how our suite of products addresses real-world veterinary challenges. The TRUFORMA® Bulk Acoustic Wave diagnostic platform, TRUVIEW™ fully automated digital microscope, PulseVet® shock wave platform, and VETGuardian® zero-touch remote monitor continue to break new ground with innovative applications and expansion into global markets. This conference allows us to not just tell, but also show veterinarians how these tools can transform their daily practice and elevate the standard of care they provide."

The company is sponsoring the following presentations by leading experts in veterinary medicine:

  • Shadi J. Ireifej, DVM DACVS presents "Like Breathing Through a Straw - Brachycephalic Airway Syndrome" on Monday, October 14th from 9:15 am - 10:15 am

  • Adam Christman, DVM, MBA presents "Pain, Pain Go Away! These Modalities Are Here to Stay!" on Monday, October 14th from 1:30 pm - 2:30 pm

  • Steve Dale, CABC presents "How to Mess with Separation Distress" on Tuesday, October 15th from 2:45 pm - 3:45 pm

Zomedica will be exhibiting at Booth #217 during the Fetch Coastal Conference.

About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW™ digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. An NYSE American company, Zomedica grew revenue 33% in 2023 to $25 million and maintains a strong balance sheet with approximately $83 million in liquidity as of June 30, 2024. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.

Follow Zomedica

Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including meeting distribution obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555

SOURCE: Zomedica Corp.



View the original press release on accesswire.com

FAQ

When and where is Zomedica (ZOM) sponsoring educational presentations at the Fetch Coastal Conference?

Zomedica is sponsoring educational presentations at the Fetch Coastal Conference in Atlantic City, NJ from October 14-16, 2024.

What products will Zomedica (ZOM) showcase at the Fetch Coastal Conference?

Zomedica will showcase its TRUFORMA® diagnostic platform, TRUVIEW™ digital microscope, PulseVet® shock wave platform, and VETGuardian® remote monitor at the conference.

Who are the experts presenting at Zomedica's (ZOM) sponsored sessions during the Fetch Coastal Conference?

The experts presenting at Zomedica's sponsored sessions include Dr. Shadi J. Ireifej, Dr. Adam Christman, and Steve Dale, CABC.

Where can attendees find Zomedica's (ZOM) booth at the Fetch Coastal Conference?

Zomedica will be exhibiting at Booth #217 during the Fetch Coastal Conference.

Zomedica Corp.

NYSE:ZOM

ZOM Rankings

ZOM Latest News

ZOM Stock Data

120.75M
949.95M
1.78%
8.63%
5.12%
Medical Devices
Pharmaceutical Preparations
Link
United States of America
ANN ARBOR